Tempus Labs applies AI to clinical and molecular data to enable precision medicine decisions in oncology.
Tempus Labs builds AI-powered platforms that analyze genomic sequencing data alongside clinical records to help physicians make personalized treatment decisions. The company's technology matches cancer patients to targeted therapies, clinical trials, and prognostic insights based on molecular profiling.
Founded by Eric Lefkofsky after a personal experience with cancer care, Tempus has expanded beyond oncology into depression, infectious disease, and cardiology. The platform serves healthcare providers, pharmaceutical companies, and researchers seeking to accelerate the development and delivery of precision medicine.
Ataraxis AI
Ataraxis Breast
ataraxis.ai
Fuze Health
Healthcare Data and Analytics Platform
fuzehealth.com
Cofactor Genomics
ImmunoPrism
cofactorgenomics.com
| Attribute | Genomic Profiling for Precision Oncology | Ataraxis Breast | Healthcare Data and Analytics Platform | ImmunoPrism | |
|---|---|---|---|---|---|
| Provider |  | | | | |
| Founded | 2015 | 2023 | 2024 | 2015 | |
| Sells To | — | Healthcare Providers | Enterprise | Enterprise | |
| Pricing Model | Software | B2B | B2B | Recurring, Software | |
| Ownership | Venture-backed | Private | Private | Venture-backed |
Provider
Founded 2015
Sells To —
Pricing Model Software
Ownership Venture-backed
Provider
Founded 2023
Sells To Healthcare Providers
Pricing Model B2B
Ownership Private
Provider
Founded 2024
Sells To Enterprise
Pricing Model B2B
Ownership Private
Provider
Founded 2015
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
Flatiron Health provides an oncology data platform that transforms cancer care through real-world evidence and clinical data analytics.
Tissue-based NGS test reporting TMB and MSI to guide immunotherapy.
NanoString Technologies770-gene multiplex panel profiling immune response in FFPE tumor samples.
Flatiron Health provides an oncology data platform that transforms cancer care through real-world evidence and clinical data analytics.
Tissue-based NGS test reporting TMB and MSI to guide immunotherapy.
770-gene multiplex panel profiling immune response in FFPE tumor samples.
NanoString Technologies